Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K

Olmesartan-induced enteropathy associated with cutaneous lesions

Nassim Hammoudi1, Marie Dior1, Vincent Giraud2

  • 1Department of Gastroenterology Louis Mourier Teaching Hospital Colombes France; Denis Diderot University Paris 7 Paris France.

Clinical Case Reports
|April 22, 2016
PubMed

Insights

Olmesartan, an angiotensin II receptor antagonist, can cause severe sprue-like enteropathy. This case highlights associated skin lesions, emphasizing the importance of drug suspension for reversibility.

Area of Science:

  • Gastroenterology
  • Dermatology
  • Pharmacology

Background:

  • Olmesartan is a widely prescribed angiotensin II receptor antagonist used for hypertension.
  • Sprue-like enteropathy is a serious gastrointestinal side effect associated with olmesartan therapy.
  • Duodenal villous atrophy is a characteristic histological finding in olmesartan-induced enteropathy.

Observation:

  • A patient presented with symptoms suggestive of sprue-like enteropathy.
  • The patient also developed unusual skin lesions during olmesartan treatment.
  • These clinical observations prompted an investigation into a potential link between olmesartan and both conditions.

Findings:

  • The case report details the association of olmesartan with severe sprue-like enteropathy and duodenal villous atrophy.
  • Notably, this report is the first to describe concurrent skin lesions in a patient with olmesartan-induced enteropathy.
  • Discontinuation of olmesartan led to the resolution of both gastrointestinal and dermatological symptoms.

Implications:

  • Clinicians must be aware of the potential for olmesartan to cause severe sprue-like enteropathy.
  • The association with skin lesions represents a novel finding requiring clinical attention.
  • Prompt recognition and suspension of olmesartan are crucial for the management and reversibility of these adverse effects.
Keywords:
EnteropathyOlmesartanside effectskin lesions

More Related Videos

Multimodality Diagnosis of Mesenteric Ischemia05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

1.4K
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.7K

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
885
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
909
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
604
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
735
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K